VYGR Latest Press Releases

-- August 6, 2026 --

Voyager Reports Second Quarter 2026 Financial and Operating Results Globe Newswire 4:01 PM

-- July 13, 2026 --

Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026 Globe Newswire 8:01 AM

-- June 29, 2026 --

Voyager's Tau-Targeted Gene Therapy VY1706 for Alzheimer's Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026 Globe Newswire 8:01 AM

-- June 11, 2026 --

Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference Globe Newswire 4:01 PM

-- June 1, 2026 --

Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer's Disease Globe Newswire 8:00 AM

-- May 13, 2026 --

Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer's Disease Expected H2 2026 Globe Newswire 6:01 AM

-- May 7, 2026 --

Voyager Reports First Quarter 2026 Financial and Operating Results Globe Newswire 4:01 PM

-- April 27, 2026 --

Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer's Disease Globe Newswire 4:31 PM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software